In the US, the number of cancer survivors has tripled since 1971, but these gains in survival have come at the price of second malignancies and cardiovascular disease. These are the main findings of a long-awaited report by a national scientific committee chaired by Lois B. Travis, M.D., Sc.D., of the University of Rochester Medical Center.
The Journal of the National Cancer Institute is publishing a detailed summary online March 6, 2012, and will publish the summary in hard copy on March 13. The expert scientific committee, which was convened by the National Council on Radiation Protection and Measurements (NCRP), deliberated intensely for five years as they considered some of the most important repercussions of radiation treatments and made several important conclusions and recommendations.
Their comprehensive, 425-page report will be made available in the spring. Before reports are approved and published by the NCRP, they undergo extensive peer review by an outside panel of experts, who provide substantial and critical comments that are addressed by the scientific committee. The revised report is then reviewed by all members of the NCRP before final revision and publication.
The committee's focus was on the consequences of radiation therapy, which is a cornerstone of cancer treatment and used in approximately 50 percent of all cancer cases. (Chemotherapy is addressed to a lesser degree, when it is used in combination with radiation.)
Louis S. Constine, M.D., professor and vice-chair of the URMC Department of Radiation Oncology, was a member of the NCRP scientific committee and echoed Travis' sentiments. He added that although radiation can be a life-saving therapy, it is critical that physicians and patients be alert to long-term side effects and plan appropriately for follow-up. As clinical director of the Wilmot Cancer Center's survivorship division, he is working with others to develop a program that will provide patients with a comprehensive plan for their post-cancer care.
Among the NCRP's key findings:
- Newer radiotherapy treatment methods and techniques result in a different distribution of the radiation to organs and tissue than older treatment regimens. However, the current models used to assess risk of second malignancies and cardiovascular disease are often based on older treatment regimens. Newer risk-prediction models should be based on the dose absorbed by the organ and the type of radiation prescribed.
- Once a patient develops a second primary cancer, few studies have gone on to describe survival after the diagnosis of the second malignancies.
- Establishing a research infrastructure that can be used by the many disciplines involved in the care of survivors is important.
- Specifically, follow-up studies of cancer survivors should evaluate populations treated with modern radiotherapy methods such as tomotherapy, cyber knife, etc., and at reduced field sizes and lower dosages.
- More studies are needed to analyze all aspects of the relationship between radiation dose and risk of second malignancies and heart disease.
- Long-term, large-scale studies are needed to follow cancer survivors of all ages, but particularly those who are adolescents and young adults, and characterize their risks as they age.
- Studies are needed to understand the molecular and genetic underpinnings of radiotherapy-associated late health effects, with a particular focus on patients who develop two or more primary cancers after radiation treatment.
- Modern radiation techniques and lower doses results in a much smaller risk of cardiovascular problems for patients. However, an important non-cancer cause of death for some survivors is radiation-related heart disease, including pericardial disease, coronary artery disease, valvular dysfunction, conduction abnormalities, and stroke.